NasdaqGS:INSMBiotechs
Insmed (INSM) Valuation Check After BiRCh Trial Setback and Respiratory Pipeline Shift
Insmed (INSM) has been on a bumpy ride after its Phase 2b BiRCh trial in chronic rhinosinusitis without nasal polyps failed to hit efficacy goals, forcing the company to halt that indication.
See our latest analysis for Insmed.
The selloff after the BiRCh miss has clearly cooled near-term enthusiasm, with a 7-day share price return of negative 10.75 percent and a 30-day share price return of negative 11.57 percent. However, the 90-day share price return of 20.9 percent and exceptional 3-year...